SCHEMBL26969413

SCHEMBL26969413

Cc1ccc(S(=O)(=O)n2cc(B(O)O)c3nc(C)ccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
UBE2N P61088 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.40
ALDH3A1 P30838 2/20 0.40
POLB P06746 2/20 0.40
HTT P42858 2/20 0.40
NOD1 Q9Y239 1/20 0.40
ALOX5 P09917 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HTR6 P50406 4/20 0.38
PKM P14618 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.37
EGFR P00533 1/20 0.37
ALK Q9UM73 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969417 0.81 CA1 (0.50) KDM4EUBE2NL3MBTL1ALDH3A1POLB
SCHEMBL15332261 0.81 L3MBTL1 (0.49) KDM4EUBE2NL3MBTL1ALDH3A1POLB
SCHEMBL26969488 0.75 L3MBTL1 (0.40) KDM4EUBE2NL3MBTL1ALDH3A1POLB
SCHEMBL29402217 0.74 KDM4E (0.68) KDM4EUBE2NL3MBTL1ALDH3A1POLB
SCHEMBL1723740 0.74 KDM4E (0.68) KDM4EUBE2NL3MBTL1ALDH3A1POLB
SCHEMBL14637084 0.73 PTGDR2 (0.49) KDM4EUBE2NL3MBTL1ALOX5HTR6
SCHEMBL1612680 0.73 HTR6 (0.50) KDM4EUBE2NL3MBTL1ALOX5HTR6
SCHEMBL14631810 0.71 ALDH1A1 (0.48) KDM4EUBE2NL3MBTL1ALOX5ALDH1A1
SCHEMBL29951204 0.71 HTR6 (0.61) HTR6
SCHEMBL17463066 0.71 HTT (0.51) L3MBTL1ALDH3A1POLBHTTNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARAMCEUTICA NV (BE) 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB KDM4E 1209/4885UBE2N 2540/4885L3MBTL1 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.